
Plus: translational highlights and Sarepta’s path to a gene therapy approval
By Jeff Cranmer, Executive Editor
February 21, 2024 2:18 AM UTC
Off switches and non-viral delivery technologies may be the solution to CAR T therapies’ most recent safety problem. On the latest BioCentury This Week podcast, BioCentury’s editors discuss alternative CAR T technologies already in development that avoid or reduce the risk of secondary malignancy.
The editors also discuss the world-first approval of a tumor-infiltrating lymphocyte (TIL) therapy from Iovance Biotherapeutics Inc. (NASDAQ:IOVA), highlights from BioCentury’s most recent survey of the translational literature in the Distillery, and the path to approval for Elevidys delandistrogene moxeparvovec, a gene therapy from Sarepta Therapeutics Inc. (NASDAQ:SRPT) for Duchenne muscular dystrophy.
Join BioCentury, BayHelix and McKinsey March 4-6 in Singapore for the third East-West Biopharma Summit. For information on how to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact BioCentury at conferences@biocentury.com.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651488/safer-car-ts-world-s-first-til-biocentury-s-latest-podcast